2,4-Dihydroxypyridine
2,4-Dihydroxypyridine structure
|
Common Name | 2,4-Dihydroxypyridine | ||
|---|---|---|---|---|
| CAS Number | 626-03-9 | Molecular Weight | 111.099 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 509.8±30.0 °C at 760 mmHg | |
| Molecular Formula | C5H5NO2 | Melting Point | 272-276 °C(lit.) | |
| MSDS | Chinese USA | Flash Point | 262.1±24.6 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Synthesis of diazaphenoxathiin nucleosides from 3-deazauridine and their chemical properties.
Nucleic Acids Symp. Ser. (12) , 13-6, (1983) New method for a synthesis of diazaphenoxathiin skeleton from 3-deazauracil derivatives is reported. It became possible to convert 3-deazauridine to 3-deazacytidine via an excellent intermediate "diazaphenoxathiin sulfoxide derivative". |
|
|
Structure-activity relationship of ligands of dihydrouracil dehydrogenase from mouse liver.
Biochem. Pharmacol. 38(9) , 1471-80, (1989) One hundred and five nucleobase analogues were screened as inhibitors of dihydrouracil dehydrogenase (DHUDase, EC 1.3.1.2) from mouse liver. 5-Benzyloxybenzyluracil, 1-deazauracil (2,6-pyridinediol), 3-deazauracil (2,4-pyridinediol), 5-benzyluracil, 5-nitroba... |
|
|
[Presynaptic effects of aminopyridines on the neuromuscular junction of vertebrates].
J. Pharmacol. 16 Suppl 2 , 109-44, (1985) In this review the effects of aminopyridines and chemically related compounds are documented in an attempt to analyse the mechanism underlying their presynaptic actions at the vertebrate neuromuscular junction. Aminopyridines and related compounds are of part... |
|
|
Sample preparation and estimation of plasma concentration of 3-deazauridine by high-performance liquid chromatography.
Ther. Drug Monit. 5(4) , 491-6, (1983) A rapid and simple procedure for liquid chromatographic analysis of plasma 3-deazauridine (3-DU), an antineoplastic agent, was developed. The plasma was extracted with methanolic silver acetate to remove interfering ultraviolet-absorbing materials and the 3-D... |
|
|
Synthesis and antitumour activity of 4-hydroxy-2-pyridone derivatives.
Eur. J. Med. Chem. 35(5) , 545-52, (2000) 4-hydroxy-2-pyridone derivatives 2 were prepared by reaction of 3-amino-3-dialkylaminopropenoates with bis(2,4, 6-trichlorophenyl)malonate. These compounds were further reacted with a set of aldehydes to give bis(pyridyl)methanes 3 and 4. The newly synthesize... |
|
|
New bis(pyridyl)methane derivatives from 4-hydroxy-2-pyridones: synthesis and antitumoral activity
Eur. J. Med. Chem. 38(1) , 37-47, (2003) Bis(pyridyl)methane derivatives 5– 40 were obtained from the reaction of 4-hydroxy-2-pyridones 3 and 4 with aldehydes. Compounds 5– 40 were evaluated for cytotoxic activity against a panel of 60 human cancer cell lines by the National Cancer Institute and som... |
|
|
Effects of pyrimidine nucleoside phosphorylase inhibitors on hepatic fluoropyrimidine elimination in the rat.
Cancer Res. 49(10) , 2567-73, (1989) The breakdown of 5-fluoro-2'-deoxyuridine (FdUrd) to 5-fluorouracil (FUra) is catalyzed by the pyrimidine nucleoside phosphorylases, uridine phosphorylase and thymidine phosphorylase. The effects of nucleoside phosphorylase inhibitors on FdUrd and FUra elimin... |
|
|
Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine).
Drug Metab. Dispos. 37(7) , 1375-7, (2009) S-1 is an oral anticancer agent that combines tegafur, a prodrug of 5-fluorouracil (5-FU), and 5-chloro-2,4-dihydroxypyridine (CDHP), an inhibitor of dihydropyrimidine dehydrogenase. We examined the effects of aging on the pharmacokinetics of the components o... |